Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus

Hala Ahmadieh,1 Nisrine Ghazal,2 Sami T Azar3 1Faculty of Medicine, Clinical Sciences Department, Beirut Arab University, 2Department of Endocrinology and Metabolism, American University of Beirut, Beirut, Lebanon; 3Department of Internal Medicine, Division of Endocrinology, American University of B...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ahmadieh H, Ghazal N, Azar ST
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	SGLT 2 Inhibitors Type I Diabetes Mellitus Glycemic Control Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/063057c90aec4777bcf2f989ab4ead74
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:063057c90aec4777bcf2f989ab4ead74
record_format	dspace
spelling	oai:doaj.org-article:063057c90aec4777bcf2f989ab4ead742021-12-02T00:04:06ZRole of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus1178-7007https://doaj.org/article/063057c90aec4777bcf2f989ab4ead742017-05-01T00:00:00Zhttps://www.dovepress.com/role-of-sodium-glucose-cotransporter-2-inhibitors-in-type-i-diabetes-m-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Hala Ahmadieh,1 Nisrine Ghazal,2 Sami T Azar3 1Faculty of Medicine, Clinical Sciences Department, Beirut Arab University, 2Department of Endocrinology and Metabolism, American University of Beirut, Beirut, Lebanon; 3Department of Internal Medicine, Division of Endocrinology, American University of Beirut, New York, NY, USA Abstract: The burden of diabetes mellitus (DM) in general has been extensively increasing over the past few years. Selective sodium glucose cotransporter-2 (SGLT2) inhibitors were extensively studied in type 2 DM and found to have sustained urinary glucose loss, improvement of glycemic control, in addition to their proven metabolic effects on weight, blood pressure, and cardiovascular benefits. Type 1 DM (T1D) patients clearly depend on insulin therapy, which till today fails to achieve the optimal glycemic control and metabolic targets that are needed to prevent risk of complications. New therapies are obviously needed as an adjunct to insulin therapy in order to try to achieve optimal control in T1D. Many oral diabetic medications have been tried in T1D patients as an adjunct to insulin treatment and have shown conflicting results. Adjunctive use of SGLT2 inhibitors in addition to insulin therapies in T1D was found to have the potential to improve glycemic control along with decrease in the insulin doses, as has been shown in certain animal and short-term human studies. Furthermore, larger well-randomized studies are needed to better evaluate their efficacy and safety in patients with T1D. Euglycemic diabetic ketoacidosis incidences were found to be increased among users of SGLT2 inhibitors, although the incidence remains very low. Recent beneficial effects of ketone body production and this shift in fuel energetics have been suggested based on the findings of protective cardiovascular benefits associated with one of the SGLT2 inhibitors. Keywords: glycemic control, glycosylated hemoglobin, euglucemic diabetic ketoacidosis, oral antidiabeticsAhmadieh HGhazal NAzar STDove Medical PressarticleSGLT 2 InhibitorsType I Diabetes MellitusGlycemic ControlSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 10, Pp 161-167 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	SGLT 2 Inhibitors Type I Diabetes Mellitus Glycemic Control Specialties of internal medicine RC581-951
spellingShingle	SGLT 2 Inhibitors Type I Diabetes Mellitus Glycemic Control Specialties of internal medicine RC581-951 Ahmadieh H Ghazal N Azar ST Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
description	Hala Ahmadieh,1 Nisrine Ghazal,2 Sami T Azar3 1Faculty of Medicine, Clinical Sciences Department, Beirut Arab University, 2Department of Endocrinology and Metabolism, American University of Beirut, Beirut, Lebanon; 3Department of Internal Medicine, Division of Endocrinology, American University of Beirut, New York, NY, USA Abstract: The burden of diabetes mellitus (DM) in general has been extensively increasing over the past few years. Selective sodium glucose cotransporter-2 (SGLT2) inhibitors were extensively studied in type 2 DM and found to have sustained urinary glucose loss, improvement of glycemic control, in addition to their proven metabolic effects on weight, blood pressure, and cardiovascular benefits. Type 1 DM (T1D) patients clearly depend on insulin therapy, which till today fails to achieve the optimal glycemic control and metabolic targets that are needed to prevent risk of complications. New therapies are obviously needed as an adjunct to insulin therapy in order to try to achieve optimal control in T1D. Many oral diabetic medications have been tried in T1D patients as an adjunct to insulin treatment and have shown conflicting results. Adjunctive use of SGLT2 inhibitors in addition to insulin therapies in T1D was found to have the potential to improve glycemic control along with decrease in the insulin doses, as has been shown in certain animal and short-term human studies. Furthermore, larger well-randomized studies are needed to better evaluate their efficacy and safety in patients with T1D. Euglycemic diabetic ketoacidosis incidences were found to be increased among users of SGLT2 inhibitors, although the incidence remains very low. Recent beneficial effects of ketone body production and this shift in fuel energetics have been suggested based on the findings of protective cardiovascular benefits associated with one of the SGLT2 inhibitors. Keywords: glycemic control, glycosylated hemoglobin, euglucemic diabetic ketoacidosis, oral antidiabetics
format	article
author	Ahmadieh H Ghazal N Azar ST
author_facet	Ahmadieh H Ghazal N Azar ST
author_sort	Ahmadieh H
title	Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
title_short	Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
title_full	Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
title_fullStr	Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
title_full_unstemmed	Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
title_sort	role of sodium glucose cotransporter-2 inhibitors in type i diabetes mellitus
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/063057c90aec4777bcf2f989ab4ead74
work_keys_str_mv	AT ahmadiehh roleofsodiumglucosecotransporter2inhibitorsintypeidiabetesmellitus AT ghazaln roleofsodiumglucosecotransporter2inhibitorsintypeidiabetesmellitus AT azarst roleofsodiumglucosecotransporter2inhibitorsintypeidiabetesmellitus
_version_	1718403906033156096

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus

Ejemplares similares